Clinical Trials Logo

Macular Degeneration clinical trials

View clinical trials related to Macular Degeneration.

Filter by:

NCT ID: NCT06330220 Completed - Clinical trials for Age-Related Macular Degeneration

Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity

Start date: February 10, 2021
Phase: Phase 4
Study type: Interventional

Although the number of wet AMD patients with the better visual acuity is increasing, the visual improvement in patients with the better vision may not be so significant after anti-vascular endothelial growth factor (VEGF) treatments because of 'ceiling effect'. The aim of current study is to investigate the improvement of visual function after aflibercept treatments using microperimetry in wet AMD patients with the better baseline visual acuity (≥20/40).

NCT ID: NCT06319872 Not yet recruiting - Clinical trials for Alcohol Use Disorder

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.

NCT ID: NCT06305416 Recruiting - Clinical trials for Diabetic Retinopathy

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Start date: March 20, 2024
Phase: Phase 3
Study type: Interventional

Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma constituents into the surrounding retina and consequently retinal edema. Thickening of the basement membrane and reduction in the number of pericytes are believed to lead to increased permeability and incompetence of the retinal vasculature. This compromise of the blood-retinal barrier leads to the leakage of plasma constituents into the surrounding retina with subsequent retinal edema. Hypoxia produced by this mechanism can also stimulate the production of vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) increases retinal vascular permeability, causes breakdown of the blood-retina barrier and results in retinal edema. Diabetic macular edema (DME) is the most common cause of visual reduction in patients with Diabetes Mellitus. The prevalence of DME globally is around 6.8 %. Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of blindness worldwide. DME is a complication of diabetic retinopathy that affects the macula, which is located at the center of the retina and responsible for central vision. Bangladesh is the 10th country in the world for the number of adults living with diabetes with some 7.1 million (5.3-12.0). In Bangladesh, it is therefore expected that diabetic secondary complications, like DR, will increase along with the rising trend of diabetes mellitus. The use of therapeutic monoclonal antibodies has revolutionized in the treatment of many diseases. In recent years, millions of patients have been successfully treated with these biological agents. Ranibizumab is one such therapeutic monoclonal antibody for intraocular use. Ranibizumab is a humanized, recombinant, immunoglobulin G1 monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A) and thus prevents choroidal neovascularization. The small size of ranibizumab allows for enhanced diffusion into the retina and choroid.

NCT ID: NCT06300476 Active, not recruiting - Stargardt Disease 1 Clinical Trials

Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)

Start date: November 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of JWK006 in Stargardt Disease(STGD1). JWK006 is packed by adeno-associated virus vector that expressing ABCA4 gene.

NCT ID: NCT06264947 Enrolling by invitation - Clinical trials for Age-related Macular Degeneration

Efficacy of Laser Acupuncture on Zanzhu (BL02) for Dry Age-related Macular Degeneration

Start date: January 26, 2024
Phase: N/A
Study type: Interventional

This study is to see if laser acupuncture is a better way to treat dry-AMD (Age-related Macular Degeneration) compared to sham laser acupuncture, in the aspect of visual acuity. Investigators planed to recruit participants who are diagnosed with dry-AMD, and not younger than 20 years old. Before the study, investigators will measure the participants' BCVA (Best Corrected Visual Acuity), and then practice laser acupuncture and sham-laser acupuncture on experiment group and control group respectively. After the 4-week study, investigators will measure the participants' BCVA again.

NCT ID: NCT06262737 Recruiting - Clinical trials for Diabetic Macular Edema

Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol

PISO
Start date: September 30, 2023
Phase:
Study type: Observational

The purpose of this study is to assess the sensation of ocular dry eye symptom after an intravitreal injection of anti-VEGF.

NCT ID: NCT06241625 Recruiting - Clinical trials for Age-Related Macular Degeneration

Virtual Reality Based Vision Test in Patients With AMD

GA-001
Start date: October 20, 2022
Phase: N/A
Study type: Interventional

To assess the usability, tolerability, and repeatability of the set of VR headset-based tasks.

NCT ID: NCT06237127 Not yet recruiting - Clinical trials for Age-Related Macular Degeneration

Effects of Goji vs. Fiber on Macular Degeneration

GOJI
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this project is to conduct a clinical trial in 60 participants ranging from age 50-80 with small drusen who are at-risk for age-related macular degeneration (AMD). The study will evaluate the effects of 28g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles..

NCT ID: NCT06231121 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

Start date: December 1, 2023
Phase:
Study type: Observational

The goal of this retrospective single-center chart review is to establish the response rate, efficacy and safety of a single dose of intravitreal faricimab injection in real-world patients with aflibercept- and ranibizumab-resistant neovascular age-related macular degeneration.

NCT ID: NCT06229665 Recruiting - Clinical trials for Dry Age-related Macular Degeneration

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

Start date: October 25, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.